Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Total Current Liabilities of $58.9 million for Q1 2026, up 236.62% year-over-year from $17.5 million in Q1 2025, and up 135.69% quarter-over-quarter from $25.0 million in Q4 2025.
Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Total Current Liabilities for 7 consecutive years, with $58.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 236.62% year-over-year to $58.9 million; the TTM figure through Mar 2026 stood at $58.9 million (up 236.62% YoY), while the FY2025 annual figure was $25.0 million, up 43.18% from the prior year.
- Total Current Liabilities climbed to $58.9 million in Q1 2026 per JANX's latest filing, from $25.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $58.9 million in Q1 2026 and bottomed at $10.6 million in Q1 2024.
- Historically, Total Current Liabilities has averaged $19.3 million across 5 years, with a median of $16.5 million in 2022.
- Annual changes were most pronounced in 2024 — Total Current Liabilities plunged 35.52% — and 2026, when it jumped 236.62%.
- Janux Therapeutics' Total Current Liabilities stood at $16.5 million in 2022, then decreased by 21.05% to $13.0 million in 2023, then jumped by 33.96% to $17.5 million in 2024, then jumped by 43.18% to $25.0 million in 2025, then soared by 135.69% to $58.9 million in 2026.
- Business Quant data shows JANX's Total Current Liabilities at $58.9 million in Q1 2026, $25.0 million in Q4 2025, and $27.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 60.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.15 Mn |
| Mar 31, 2026 | 58.92 Mn |
| Dec 31, 2025 | 25.00 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 21.38 Mn |
| Mar 31, 2025 | 17.50 Mn |
| Dec 31, 2024 | 17.46 Mn |
| Sep 30, 2024 | 17.17 Mn |
| Jun 30, 2024 | 11.55 Mn |
| Mar 31, 2024 | 10.61 Mn |
| Dec 31, 2023 | 13.03 Mn |
| Sep 30, 2023 | 14.47 Mn |
| Jun 30, 2023 | 17.90 Mn |
| Mar 31, 2023 | 16.11 Mn |
| Dec 31, 2022 | 16.51 Mn |
| Sep 30, 2022 | 16.34 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 12.52 Mn |
| Dec 31, 2021 | 12.80 Mn |
| Sep 30, 2021 | 12.47 Mn |